Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A condition in males that affects sexual development. It is characterized by underdevelopment of the Leydig cells, which are cells in the testes that secrete male sex hormones (androgens) and are important for male sexual development. Individuals with LCH have a typical male genetic make-up (46, XY), but due to lowered levels of androgens, may have a range of genital (reproductive organ) differences. Individuals with LCH may have a small penis (micropenis),the opening of the urethra may be located on the underside of the penis (hypospadias), or the scrotum may be divided into two halves (bifid scrotum). Given these differences in development, the external genitalia may not appear clearly male or female (ambiguous genitalia). Some individuals with LCH can have female external genitalia and small testes that have not descended and are located in the pelvis, abdomen, or groin. This may be referred to as type 1, whereas less severe cases might be called type 2. LCH is inherited in an autosomal recessive manner and is caused by mutations in the LHCGR gene.Although there is no specific treatment or cure for LCH, there may be ways to manage the symptoms. A team of doctors or specialists is often needed to figure out the treatment options for each person.
Estimated prevalence: <1 in 1,000,000 (VERY_RARE).
No clinical trials have been registered for Leydig cell hypoplasia.
22 publications have been identified in PubMed for Leydig cell hypoplasia. Research spans Basic Science / Preclinical (59%), Review / Meta-Analysis (18%), and Case Report / Case Series (18%).
Research Type | Count | % of Total |
|---|---|---|
Laboratory research | 13 | 59% |
Data assembled from 3 of 12 sources · Last updated Sep 19, 2026, 10:19 PM UTC
European rare disease database
Genetic and Rare Diseases Info Center
Common questions about Leydig cell hypoplasia
4 |
18% |
Patient case studies | 4 | 18% |
Clinical study results | 1 | 5% |
Li H (2026). [PMID: 42000711](https://pubmed.ncbi.nlm.nih.gov/42000711/). *Nat Commun*. [Basic Science / Preclinical]
Uekama K (2026). [PMID: 42248344](https://pubmed.ncbi.nlm.nih.gov/42248344/). *J Shoulder Elbow Surg*. [Basic Science / Preclinical]
Witte L (2025). [PMID: 40956343](https://pubmed.ncbi.nlm.nih.gov/40956343/). *Urologie*. [Review / Meta-Analysis]
Wang X (2025). [PMID: 39897557](https://pubmed.ncbi.nlm.nih.gov/39897557/). *Theranostics*. [Basic Science / Preclinical]
Cavaggion C (2025). [PMID: 40368129](https://pubmed.ncbi.nlm.nih.gov/40368129/). *J Back Musculoskelet Rehabil*. [Clinical Trial Publication]
Estermann MA (2025). [PMID: 40295478](https://pubmed.ncbi.nlm.nih.gov/40295478/). *Nat Commun*. [Basic Science / Preclinical]
Soares DM (2025). [PMID: 41631229](https://pubmed.ncbi.nlm.nih.gov/41631229/). *Cureus*. [Case Report / Case Series]
Gong MX (2025). [PMID: 39674121](https://pubmed.ncbi.nlm.nih.gov/39674121/). *Phytomedicine*. [Basic Science / Preclinical]
Miles TK (2025). [PMID: 40741169](https://pubmed.ncbi.nlm.nih.gov/40741169/). *Front Endocrinol (Lausanne)*. [Basic Science / Preclinical]
Jin KX (2025). [PMID: 39962787](https://pubmed.ncbi.nlm.nih.gov/39962787/). *Zhongguo Dang Dai Er Ke Za Zhi*. [Case Report / Case Series]